INOVIO PHARMACEUTICALS, INC. - 8-K Filing

Inovio reports Q3 2026 net loss of $49.2 million and announces FDA accelerated approval for VOCERYQ (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $INO

Read the full article at SEC EDGAR

Part of the story Noble Corp plc - 8-K Filing (63 articles)

More Regulatory news